[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596062":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":37,"locations":45,"responsibleParty":69,"collaborators":71,"id":75,"slug":26,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":26,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":26,"enrollmentInfo":83,"targetDuration":26,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":26,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Varenicline","EXPERIMENTAL","Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) plus brief cessation advice with a counselor and self-management resources.",[13],"Drug: Varenicline 1mg BID",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will randomly be assigned to 12-weeks of matching placebo plus brief cessation advice with a counselor and self-management resources.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Varenicline 1mg BID","12 weeks following the standard titration of 1 mg, twice daily",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Matching placebo twice daily",[15],[31,34],{"name":32,"affiliation":5,"role":33},"Lisa Fucito, PhD","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Benjamin Toll, PhD","Medical University of South Carolina",[38,42],{"name":32,"role":39,"phone":40,"phoneExt":26,"email":41},"CONTACT","2032001470","lisa.fucito@yale.edu",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Michael Fatigate, PhD","Michael.fatigate@yale.edu",[46,59],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":26},"Yale Cancer Center\u002FSmilow Cancer Hospital at Yale-New Haven","RECRUITING","New Haven","Connecticut","06520","United States",{"type":54,"coordinates":55},"Point",[56,57],-72.92816,41.30815,{"lat":57,"lon":56},{"facility":60,"status":48,"city":61,"state":62,"zip":63,"country":52,"cosmosGeoPoint":64,"geoPoint":68,"contacts":26},"Hollings Cancer Center at MUSC (HCC)","Charleston","South Carolina","29425",{"type":54,"coordinates":65},[66,67],-79.93275,32.77632,{"lat":67,"lon":66},{"type":70,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[72],{"name":73,"class":74},"National Cancer Institute (NCI)","NIH","100596062",false,"NCT07040566","A Trial of Varenicline for E-cigarette Cessation","Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults","Inclusion Criteria:\n\n* report daily use of an e-cigarette containing nicotine\n* live in Connecticut or South Carolina\n\nExclusion Criteria:\n\n* regular use of other tobacco products besides e-cigarettes\n* medical contraindications for varenicline use\n* current treatment for tobacco cessation\n* lack proficiency in English","ALL","18 Years",{"count":84,"type":85},326,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.",[91,92,93],"E-cigarette Use","Vaping","Nicotine Dependence","2025-12-15",{"date":96,"type":97},"2025-12-17","ACTUAL",{"date":99,"type":97},"2025-10-14",{"date":101,"type":85},"2030-10-30",{"name":5,"class":6},2]